Vertex Pharmaceuticals Inc
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Total accrued expenses by Quarter
Total accrued expenses ($M) ($M)
Vertex Pharmaceuticals Total accrued expenses: $3,179M in Q2 2026, down 2.8% from a year earlier.
Latest, Q2 2026
3,179
Period ended Jun 30, 2026
Change on a year earlier
-2.8%
3,271 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
45
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Consolidated Balance Sheets & Accrued Expenses Note.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total accrued expenses ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 3,179 | -2.8% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 2,984 | +1.1% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 2,971 | +6.5% | Form 10-Q (filed 2026-08-04) ↗ |
| Q3 2025 | Sep 30, 2025 | 3,614 | +12.2% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 3,271 | +11.2% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 2,952 | +5.6% | Form 10-Q (filed 2025-05-06) ↗ |
| Q4 2024 | Dec 31, 2024 | 2,789 | +5.0% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 3,220 | +10.7% | Form 10-Q (filed 2024-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 2,940 | +13.2% | Form 10-Q (filed 2024-08-02) ↗ |
| Q1 2024 | Mar 31, 2024 | 2,796 | +20.2% | Form 10-Q (filed 2024-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 2,655 | +24.9% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2023 | Sep 30, 2023 | 2,907 | +28.4% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 2,598 | +22.6% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 2,326 | +35.2% | Form 10-Q (filed 2023-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | 2,127 | +26.7% | Form 10-K (filed 2024-02-15) ↗ |
| Q3 2022 | Sep 30, 2022 | 2,264 | +42.9% | Form 10-Q (filed 2022-10-28) ↗ |
| Q2 2022 | Jun 30, 2022 | 2,120 | +43.0% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 1,721 | +12.3% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 1,679 | +19.5% | Form 10-K (filed 2023-02-10) ↗ |
| Q3 2021 | Sep 30, 2021 | 1,585 | -7.0% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 1,483 | -4.1% | Form 10-Q (filed 2021-07-30) ↗ |
| Q1 2021 | Mar 31, 2021 | 1,532 | +21.8% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2020 | Dec 31, 2020 | 1,405 | +25.8% | Form 10-K (filed 2022-02-09) ↗ |
| Q3 2020 | Sep 30, 2020 | 1,704 | +45.1% | Form 10-Q (filed 2020-10-30) ↗ |
| Q2 2020 | Jun 30, 2020 | 1,545 | +44.6% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2020 | Mar 31, 2020 | 1,258 | +136.2% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2019 | Dec 31, 2019 | 1,117 | +16.5% | Form 10-K (filed 2021-02-11) ↗ |
| Q3 2019 | Sep 30, 2019 | 1,174 | +132.8% | Form 10-Q (filed 2019-10-31) ↗ |
| Q2 2019 | Jun 30, 2019 | 1,069 | +123.1% | Form 10-Q (filed 2019-08-01) ↗ |
| Q1 2019 | Mar 31, 2019 | 533 | +29.6% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 959 | +111.9% | Form 10-K (filed 2020-02-13) ↗ |
| Q3 2018 | Sep 30, 2018 | 504 | +33.2% | Form 10-Q (filed 2018-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | 479 | +38.8% | Form 10-Q (filed 2018-07-26) ↗ |
| Q1 2018 | Mar 31, 2018 | 411 | +47.9% | Form 10-Q (filed 2018-04-27) ↗ |
| Q4 2017 | Dec 31, 2017 | 453 | +43.6% | Form 10-K (filed 2019-02-13) ↗ |
| Q3 2017 | Sep 30, 2017 | 379 | +29.7% | Form 10-Q (filed 2017-10-30) ↗ |
| Q2 2017 | Jun 30, 2017 | 345 | +25.4% | Form 10-Q (filed 2017-07-28) ↗ |
| Q1 2017 | Mar 31, 2017 | 278 | +1.9% | Form 10-Q (filed 2017-04-28) ↗ |
| Q4 2016 | Dec 31, 2016 | 315 | +3.1% | Form 10-K (filed 2018-02-15) ↗ |
| Q3 2016 | Sep 30, 2016 | 292 | +16.9% | Form 10-Q (filed 2016-10-31) ↗ |
| Q2 2016 | Jun 30, 2016 | 275 | +33.6% | Form 10-Q (filed 2016-08-01) ↗ |
| Q1 2016 | Mar 31, 2016 | 273 | +54.1% | Form 10-Q (filed 2016-05-03) ↗ |
| Q4 2015 | Dec 31, 2015 | 306 | – | Form 10-K (filed 2017-02-23) ↗ |
| Q3 2015 | Sep 30, 2015 | 250 | – | Form 10-Q (filed 2015-10-30) ↗ |
| Q2 2015 | Jun 30, 2015 | 206 | – | Form 10-Q (filed 2015-08-04) ↗ |
| Q1 2015 | Mar 31, 2015 | 177 | – | Form 10-Q (filed 2015-05-04) ↗ |
Breakdown
What makes up total accrued expenses
Cite this data
StockData. (2026). Vertex Pharmaceuticals Total accrued expenses ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/accrued-total
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.